-
Product Insights
NewDiscoidin Domain Containing Receptor 2 – Drugs In Development, 2024
The Discoidin Domain Containing Receptor 2 pipeline drugs market research report outlays comprehensive information on the Discoidin Domain Containing Receptor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, and Central Nervous System which include indications of Solid Tumor, Gallbladder Cancer, Neurodegenerative Diseases, and Alzheimer's Disease. It also reviews key players involved in Discoidin Domain Containing...
-
Product Insights
NewEpithelial Discoidin Domain Containing Receptor 1 – Drugs In Development, 2024
The Epithelial Discoidin Domain Containing Receptor 1 pipeline drugs market research report outlays comprehensive information on the Epithelial Discoidin Domain Containing Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Respiratory, Genito Urinary System, and Central Nervous System which include indications of Solid Tumor, Liver Cancer, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Acute Renal...
-
Product Insights
NewT Cell Immunoreceptor With Ig And ITIM Domains – Drugs In Development, 2024
The T Cell Immunoreceptor With Ig And ITIM Domains pipeline drugs market research report outlays comprehensive information on the T Cell Immunoreceptor With Ig And ITIM Domains targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, and Undisclosed which include indications of Solid Tumor, Non-Small Cell Lung Cancer, and Unspecified. It also reviews key players involved in...
-
Product Insights
NewEndothelial PAS Domain Containing Protein 1 – Drugs In Development, 2024
The Endothelial PAS Domain Containing Protein 1 pipeline drugs market research report outlays comprehensive information on the Endothelial PAS Domain Containing Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Cardiovascular, Genetic Disorders, and Undisclosed which include indications of Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Pulmonary Arterial Hypertension, Von Hippel-Lindau Syndrome, and Unspecified Rare...
-
Product Insights
NewNucleotide Binding Oligomerization Domain Containing Protein 2 – Drugs In Development, 2024
The Nucleotide Binding Oligomerization Domain Containing Protein 2 pipeline drugs market research report outlays comprehensive information on the Nucleotide Binding Oligomerization Domain Containing Protein 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Gastrointestinal, Infectious Disease, and Immunology which include indications of Colorectal Cancer, Melanoma, Crohn's Disease (Regional Enteritis), Ileitis, Human Immunodeficiency Virus (HIV) Infections (AIDS),...
-
Product Insights
NewNACHT LRR And PYD Domains Containing Protein 3 – Drugs In Development, 2024
The NACHT LRR And PYD Domains Containing Protein 3 pipeline drugs market research report outlays comprehensive information on the NACHT LRR And PYD Domains Containing Protein 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Immunology, Gastrointestinal, and Genetic Disorders which include indications of Parkinson's Disease, Alzheimer's Disease, Inflammation, Unspecified Immunological Disorders, Inflammatory Bowel...
-
Product Insights
NewV Type Immunoglobulin Domain Containing Suppressor of T Cell Activation – Drugs In Development, 2024
The V Type Immunoglobulin Domain Containing Suppressor of T Cell Activation pipeline drugs market research report outlays comprehensive information on the V Type Immunoglobulin Domain Containing Suppressor of T Cell Activation targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, and Central Nervous System which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Psoriasis, Autoimmune...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTL-119 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTL-119 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTL-119 in Non-Hodgkin Lymphoma Drug Details: CTL-119 (huCTL019) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTL-119 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTL-119 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTL-119 in B-Cell Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lutikizumab in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lutikizumab in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lutikizumab in Ulcerative Colitis Drug Details: Lutikizumab is under development for...